SCHEMBL3986274

SCHEMBL3986274

NC(=O)c1cc(-c2ccc(-c3cccnc3)cc2)no1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 9/20 0.57
MKNK2 Q9HBH9 9/20 0.57
CYP2C9 P11712 2/20 0.52
CYP2C19 P33261 2/20 0.52
CYP2A6 P11509 2/20 0.52
CYP2E1 P05181 1/20 0.52
CYP2B6 P20813 1/20 0.52
IP6K1 Q92551 1/20 0.48
IP6K3 Q96PC2 1/20 0.48
IP6K2 Q9UHH9 1/20 0.48
NAMPT P43490 1/20 0.47
PIM1 P11309 1/20 0.47
PIM2 Q9P1W9 1/20 0.47
BRAF P15056 1/20 0.46
RAB9A P51151 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
DHODH Q02127 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30516607 0.94 CYP2E1 (0.57) MKNK1MKNK2CYP2C9CYP2C19CYP2A6
SCHEMBL6872027 0.94 CYP2E1 (0.57) MKNK1MKNK2CYP2C9CYP2C19CYP2A6
SCHEMBL3983330 0.90 KMO (0.51) MKNK1MKNK2CYP2C9CYP2C19CYP2A6
SCHEMBL3990124 0.84 CHUK (0.47) MKNK2CYP2C19IP6K1IP6K3IP6K2
SCHEMBL4277897 0.83 TP53 (0.45) CYP2C9CYP2C19CYP2A6CYP2E1CYP2B6
SCHEMBL3985673 0.82 RAB9A (0.64) CYP2C9CYP2C19IP6K1RAB9ASMN1; SMN2
SCHEMBL30516614 0.81 CYP2E1 (0.55) MKNK1MKNK2CYP2C9CYP2C19CYP2A6
SCHEMBL370074 0.81 CYP2E1 (0.55) MKNK1MKNK2CYP2C9CYP2C19CYP2A6
SCHEMBL23930645 0.80 CYP2A6 (0.54) CYP2C9CYP2C19CYP2A6CYP2E1CYP2B6
SCHEMBL368446 0.80 CYP2C9 (0.54) MKNK1MKNK2CYP2C9CYP2C19CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1893572-B1 FACTOR XA INHIBITORS MILLENNIUM PHARM INC (US) 2016-12-14 EP claimed
US-20090298806-A1 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. 2009-12-03 US claimed
EP-1893572-A2 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-03-05 EP claimed
US-20060100193-A1 5-Chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)thiophene-2-carboxamide; 5-Chloro-thiophene-2-carboxylic acid (3-p-tolyl-4,5-dihydro-isoxazol-5-ylmethyl)-amide; undesirable thrombosis inhibitor MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-05-11 US claimed
WO-2006002099-A2 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-01-05 WO claimed
EP-1893572-B1 FACTOR XA INHIBITORS MILLENNIUM PHARM INC (US) 2016-12-14 EP disclosed
US-8377974-B2 Factor Xa inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-02-19 US disclosed
US-20120178733-A1 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. 2012-07-12 US disclosed
US-20090298806-A1 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. 2009-12-03 US disclosed
US-7521470-B2 Factor Xa inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-04-21 US disclosed
EP-1893572-A2 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-03-05 EP disclosed
US-20060100193-A1 5-Chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)thiophene-2-carboxamide; 5-Chloro-thiophene-2-carboxylic acid (3-p-tolyl-4,5-dihydro-isoxazol-5-ylmethyl)-amide; undesirable thrombosis inhibitor MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-05-11 US disclosed
WO-2006002099-A2 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100193-A1 5-Chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-1,2,3-triazol-4-yl)methyl)thiophene-2-carboxamide; 5-Chloro-thiophene-2-carboxylic acid (3-p-tolyl-4,5-dihydro-isoxazol-5-ylmethyl)-amide; undesirable thrombosis inhibitor TFPI, TFPI2, F12 MKNK1 3512/4885MKNK2 3410/4885CYP2C9 13/4885
US-20090298806-A1 FACTOR XA INHIBITORS TFPI, F12, F11 MKNK1 4374/4885MKNK2 4325/4885CYP2C9 51/4885
US-20120178733-A1 FACTOR XA INHIBITORS TFPI, F12, F11 MKNK1 4374/4885MKNK2 4325/4885CYP2C9 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.